SPY330.65-3.85 -1.15%
DIA276.52-2.38 -0.85%
IXIC10,793.28-117.00 -1.07%

TCR2 Therapeutics Q1 EPS $(0.650) Up From $(4.850) YoY

TCR2 Therapeutics (NASDAQ:TCRR) reported quarterly losses of $(0.650) per share. This is a 86.6 percent increase over losses of $(4.850) per share from the same period last year.

Benzinga · 05/14/2020 10:46

TCR2 Therapeutics (NASDAQ:TCRR) reported quarterly losses of $(0.650) per share. This is a 86.6 percent increase over losses of $(4.850) per share from the same period last year.